Phio Pharmaceuticals: A Disruptor in the Making

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has made waves in the biotechnology industry with its innovative INTASYL® siRNA gene silencing technology, designed to enhance the body's immune cells' ability to fight cancer. The company's groundbreaking work has earned it a nomination for the Technology Disruptor of the Year Award, to be presented during Advanced Therapies Week 2025 in Dallas.

Phio's nomination highlights its patented INTASYL technology, which can silence any gene in the human genome with high specificity across various cell types and tissues. This unique siRNA platform targets and silences virtually any gene, making it a powerful tool for immuno-oncology therapeutics. Unlike other siRNA platforms, INTASYL is self-delivering, eliminating the need for formulation enhancements or manipulations to reach its target.

The company's Phase 1b clinical trial has shown promising results, with one patient with cutaneous squamous cell carcinoma achieving a complete response (100% tumor clearance) and another patient with squamous cell carcinoma achieving a partial response (90% tumor clearance). These results demonstrate the potential of INTASYL in treating skin cancers, such as cutaneous squamous cell carcinoma and melanoma.

Phio Pharmaceuticals' success can be attributed to its ability to target specific genes and cancer types effectively. The company's INTASYL compound PH-762, which targets PD-1, has shown potential as a non-surgical treatment for these skin cancers. The company's focus on immuno-oncology therapeutics and its commitment to driving change in the industry have positioned it as a strong contender for the Technology Disruptor of the Year Award.


As the biotechnology industry continues to evolve, companies like Phio Pharmaceuticals are at the forefront of innovation, pushing the boundaries of what is possible in cancer treatment. With its nomination for the Technology Disruptor of the Year Award, Phio Pharmaceuticals has solidified its position as a leader in the field, poised to make a significant impact on the future of immuno-oncology therapeutics.


In conclusion, Phio Pharmaceuticals' nomination for the Technology Disruptor of the Year Award is a testament to the company's groundbreaking work in the field of immuno-oncology therapeutics. With its innovative INTASYL technology and promising clinical trial results, Phio Pharmaceuticals is well-positioned to continue disrupting the industry and making a significant impact on cancer treatment.